Oytun Ulus’ Post

Watch our on-demand webinar on overcoming upstream and downstream process barriers for large-scale AAV production! Watch our esteemed speakers from #EncodedTherapeutics and #ThermoFisherScientific share their valuable insights and strategies to optimize your AAV manufacturing process, ultimately accelerating the development of safe and effective gene therapies. Watch here: https://lnkd.in/gaXj4Vbf Key Takeaways: ✅ Discover an end-to-end solution for the development and commercial production of AAV. ✅ Learn about new products and technologies that can enhance production efficiency, address regulatory concerns, and facilitate the scale-up of AAV production protocols. ✅ Gain a comprehensive understanding of how gene therapy developers are currently tackling critical manufacturing challenges. Stream today to learn more about gene therapy manufacturing!

Watch our on-demand webinar on overcoming upstream and downstream process barriers for large-scale AAV production! Watch our esteemed speakers from #EncodedTherapeutics and #ThermoFisherScientific share their valuable insights and strategies to optimize your AAV manufacturing process, ultimately accelerating the development of safe and effective gene therapies. Watch here: https://lnkd.in/gaXj4Vbf Key Takeaways: ✅ Discover an end-to-end solution for the development and commercial production of AAV. ✅ Learn about new products and technologies that can enhance production efficiency, address regulatory concerns, and facilitate the scale-up of AAV production protocols. ✅ Gain a comprehensive understanding of how gene therapy developers are currently tackling critical manufacturing challenges. Stream today to learn more about gene therapy manufacturing!

#cell and #gene #therapy #facilitydesign The rapidly evolving field of cell and gene therapies presents unique challenges and requirements, necessitating specialized cleanroom design. If you're contemplating developing cell and gene therapy products, it's essential to establish a cleanroom environment specifically tailored for their manufacturing.

Watch our on-demand webinar on overcoming upstream and downstream process barriers for large-scale AAV production! Watch our esteemed speakers from Encoded Therapeutics and Thermo Fisher Scientific share their valuable insights and strategies to optimize your AAV manufacturing process, ultimately accelerating the development of safe and effective gene therapies. Key Takeaways: ✅ Discover an end-to-end solution for the development and commercial production of AAV. ✅ Learn about new products and technologies that can enhance production efficiency, address regulatory concerns, and facilitate the scale-up of AAV production protocols. ✅ Gain a comprehensive understanding of how gene therapy developers are currently tackling critical manufacturing challenges.

Please add CellReady™ to the CGT list. CellReady™ is the only CGT CDMO that is solely dedicated to G-Rex-centric manufacturing. We also believe that CellReady™ is the only CGT CDMO that has an ownership structure that is absent venture funding or any other form of ownership structure that imposes a need to generate significant financial profit. Why is this important? It frees CellReady™ to provide CGT entities what they need most and have least. TIME and MONEY How is that possible? CellReady™ is playing the Infinite Game and has a mindset of abundance. It is willing and able to run close to breakeven with minimal profit. No quarterly financial targets, no need to drive towards a lucrative financial exit, no need to do anything that makes its clients become viewed as a source of money. Where does this lead? CellReady™ is likely the only CDMO with the sole goal of openly sharing its operational and technical approaches to manufacturing efficiency with the entire field of CGT, including competitive CDMOs. By doing that, CellReady™ intends to revolutionize the business model of CGT by democratizing the information that sets it apart from others. That will help set the field free of the existing time and money trap which has caused investment to dry up. With a mindset of abundance, one initiative that CellReady™ is helping to fund is a $20 million G-Rex Grant Program available at ScaleReady which provides every recipient with up to $300,000 of free products and services to accelerate their clinical enabling manufacturing work or to make manufacturing advancements for programs that are already in the clinical. Please check it out.

Another useful infographic!

With the current downturn and significant layoffs across the biopharma sector, outsourcing has become a vital component in ensuring future success for these impacted organizations. The CDMO space is incredibly rich in both volume of opportunities but also competition. Now more than ever these companies must innovate to differentiate… derisking sponsor projects through novel analytics and methods that deliver consistent results with increased speed and quality. CDMOs have a very unique opportunity right now to be the leaders and experts that hold the know how in accelerating significant advancements across complex development and production processes.

The CDMO landscape is bustling with over 400 players in small molecules, biologics, and cell and gene therapy. Singota Solutions (peep our logo in those small molecule & biologics categories) stands out with our faster pipelines and a caring, flexible, and focused approach for small batch early phase clients. Unlike larger CDMOs, we prioritize and support those who often get bypassed. Discover the Singota Solutions difference! #biomanufacturing #innovation #CDMOs #Pharma #Biotech #DrugDevelopment #SingotaSolutions BioKnow Arinjay Sarma

Droplet digital PCR (#ddPCR) is a powerful and versatile tool with applications across the advanced therapies field. In this hub, BioInsights presents a curated selection of content designed to answer your questions about the specific utility, considerations, and advantages of utilizing ddPCR from the early stages of product and process development through to clinical and commercial manufacture. Key topics include: • Key considerations when adopting droplet digital PCR for #viralvector manufacture • Detecting #HEK293 residual #DNA contamination in your cell or gene therapy products • Leveraging ddPCR for optimal #RNA therapeutic product development Visit the hub below:

Join our Cell and Gene Therapy (CGT) Virtual Event on March 20, featuring technology and process advancements in CGTs development. 👉 Register here to secure your spot! https://lnkd.in/eMZ2pPax Delivered through an interactive virtual platform, this event features over 3 hours of insightful sessions led by 7 expert scientists across the ecosystem. Our exciting topics include: • Large scale processing of mesenchymal stromal cells (MSC) and T cell immunotherapies • Integrated, cutting-edge solutions and process advancements that supports end-to-end workflow • Regulatory considerations in raw material selection from research through commericalisation • Analytical platforms to evaluate the quality, safety, and efficacy of cell-based products #celltherapy #genetherapy #cellandgenetherapy #manufacturing